seborrheic%20dermatitis
SEBORRHEIC DERMATITIS
Seborrheic dermatitis is a chronic inflammatory skin disorder characterized by fine scaling and erythema mostly confined to areas where sebaceous glands are prominent.
Pityrosporum ovale infection is common in seborrheic dermatitis.
The characteristic pattern is based on age group.
In infants it appears as cradle cap. It is a diffuse or focal scaling and crusting on the vertex of the scalp that sometimes accompanied by inflammation.
In young children, there is Tinea amiantacea which is one or several patches of dense, plate-like scales, 2-10 cm in size that appear anywhere on the scalp.
While adolescents have dandruff which are fine, dry, white, non-inflammatory scalp scaling with minor itching.
Drug Information

Indication: Relief of external thrush symptoms.

Indication: Adult & childn ≥3 mth: Eczema including atopic, infantile & discoid eczemas, prurigo nodularis, pso...

Indication: Dermatophytoses, mycoses & various fungi, pityriasis versicolor, infection & superinfection (gm +ve). ...

Indication: Psoriasis (excluding widespread plaque psoriasis), recalcitrant eczemas, lichen planus, discoid lupus erythema...

Indication: Short-term treatment & intermittent long-term therapy of mild to moderate of atopic dermatitis in non-immu...

Indication: Topical treatment of dermatophyte skin infections eg, tinea corporis, tinea cruris, tinea manus & tinea pe...

Indication: Treatment & prophylaxis of Pityriasis versicolor (localised), seborrhoeic dermatitis & pityriasis capi...

Dosage: Cap Vulvovag candidiasis 200 mg bd for 1 day or 200 mg once daily for 3 days. Pityriasis versicolor 200 mg onc

Indication: Tinea pedis, cruris, corporis & versicolor; cutaneous candidiasis.

Indication: Eczema including atopic, infantile, discoid & stasis eczema; prurigo; psoriasis; neurodermatoses including...

1  /  15
Editor's Recommendations
Most Read Articles
25 Apr 2019
A recent study has demonstrated the potential of clindamycin as a treatment alternative to antibiotic combination regardless of hidradenitis suppurativa (HS) clinical stage.
01 May 2019
New drug applications approved by US FDA as of 16 - 30 April 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.